To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

EpiDestiny, Inc. (Industry)
Overall Status
Recruiting ID
Worldwide Clinical Trials (Other)

Study Details

Study Description

Brief Summary

This is an open-label, randomized, single-dose per period, two-period, crossover study to evaluate the relative bioavailability of decitabine and tetrahydrouridine ingested as a modified-release combination formulation compared to THU and decitabine ingested as immediate-release capsules

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

This study builds on previous bioavailability studies in healthy volunteers of a larger combination dosage form of decitabine and tetrahydrouridine (THU) (5 mg/250 mg). The smaller combination dosage form being evaluated in this study (2.5 mg/100 mg) is intended to allow more precise weight band dosing, to hopefully further decrease the inter-individual variability in pharmacokinetics and pharmacodynamics.

Study Design

Study Type:
Anticipated Enrollment :
10 participants
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized, two-way crossoverRandomized, two-way crossover
None (Open Label)
Primary Purpose:
Official Title:
An Open Label, Randomized, Single Dose, Two Way Crossover, Bioavailability Study of a Combination Formulation of Decitabine/Tetrahydrouridine (2.5 mg/100 mg) Modified Release Capsules in Healthy, Fasting, Male Adults
Actual Study Start Date :
Mar 24, 2023
Anticipated Primary Completion Date :
May 3, 2023
Anticipated Study Completion Date :
Jun 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Modified release formulation of decitabine and tetrahydrouridine

A modified-release combination formulation of decitabine/THU (2.5 mg/100 mg per capsule given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.

Drug: Decitabine
Oral administration of decitabine as a single dose to healthy male subjects
Other Names:
  • DEC
  • Drug: Tetrahydrouridine
    Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
    Other Names:
  • THU
  • Active Comparator: Immediate release capsules of decitabine and tetrahydrouridine

    Capsules of THU are given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water, followed by a single oral dose of decitabine given 1 hour (± 5 min) later with approximately 240 mL (8 fluid ounces) of ambient temperature water.

    Drug: Decitabine
    Oral administration of decitabine as a single dose to healthy male subjects
    Other Names:
  • DEC
  • Drug: Tetrahydrouridine
    Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
    Other Names:
  • THU
  • Outcome Measures

    Primary Outcome Measures

    1. Peak decitabine and tetrahydrouridine concentration in plasma [0 to 24 hours]

      Maximum levels of drug (decitabine and tetrahydrouridine) in plasma over 24 hr

    2. Decitabine and tetrahydrouridine drug level exposure over 24 hr [0 to 24 hours]

      Area under the plasma concentration time profile for decitabine and tetrahydrouridine

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related procedures being performed and be able to adhere to restrictions and examination schedules.

    • Must be able to communicate with the Investigator and understand and comply with the requirements of the study.

    • Healthy male volunteers from any race between 18 to 50 years of age (inclusive), and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at screening.

    • Must have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and a weight between 60 and 100 kg (~132 to 220 lb), inclusive, at screening.

    • Subject's clinical laboratory test results have no clinically significant findings, in the opinion of the Investigator.

    • Vital signs including systolic and diastolic blood pressure, heart rate, and temperature will be assessed in the supine position after the subject has rested for at least 5 minutes. At screening, the potential subject must have a body temperature of ≤37.7°C, with systolic blood pressure between 90 and 140 mmHg (inclusive), diastolic blood pressure between 60 and 90 mmHg (inclusive), and heart rate between 40 and 100 bpm (inclusive). Vital signs criteria at each check-in and predose measurements will be at the Investigator's discretion. Out-of-range vital signs may be repeated once at the discretion of the Investigator.

    • Subjects must be free of any clinically significant disease that would interfere with the study evaluations.

    • Males with female partners must use a highly effective form of contraception (i.e., double barrier method, which includes a condom plus diaphragm with spermicide or condom plus spermicide or has had a vasectomy) or have no female partners of childbearing potential at the time of screening and for 90 days after the last dose of study treatment. Subjects must also agree not to donate sperm for the duration of the study and until 90 days after the last dose of study treatment.

    Exclusion Criteria:
    • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition, including the presence of laboratory abnormalities, that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.

    • Any serious medical condition, clinically significant laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF.

    • Tests positive for COVID-19 via polymerase chain reaction (PCR) test at check-in.

    • Recent history within 3 years of any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematologic, or other major disorders.

    • Used any prescribed systemic or topical medication within 14 days of the first dose administration.

    • Used any non-prescribed systemic (including herbal medicines, e.g. St. John's Wort) or topical medication within 7 days of the first dose administration (with the exception of vitamin/mineral supplements)

    • Subjects who have any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).

    • Exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration or currently enrolled in any investigational trials.

    • Donated blood or plasma within 8 weeks preceding the first dose administration.

    • History of relevant drug and/or food allergies.

    • Any clinically significant allergic disease (excluding nonactive hay fever).

    • Self-reported history of drug abuse of at least 2 years prior to the first dose of study treatment, and/or positive drug screening test due to illicit drugs at screening or Day 1 of each period.

    • Self-report of more than 21 units of alcohol per week (1 unit of alcohol equals approximately 12 ounces of 5% alcohol by volume [ABV] beer, 8 ounces of 7% ABV malt liquor, 5 ounces of 12% ABV wine, 1.5 ounces 40% ABV [80 proof] distilled spirits [e.g., gin, rum, vodka, whiskey, etc.]), and/or positive alcohol screen at screening or Day 1 of each period.

    • Smokers or users of other tobacco products (e.g., chewing tobacco, or those using nicotine-containing products [i.e., patches, gum]) in the 3 months prior to screening, or positive urine cotinine test.

    • Known to have serum hepatitis or known to be a carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb), or tests positive for human immunodeficiency virus (HIV) antibodies at screening.

    Contacts and Locations


    Site City State Country Postal Code
    1 Worldwide Clinical Trails Early Phase Services San Antonio Texas United States 78217

    Sponsors and Collaborators

    • EpiDestiny, Inc.
    • Worldwide Clinical Trials


    • Principal Investigator: Ingela Danielsson, MD, Worldwide Clinical Trials

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    EpiDestiny, Inc. Identifier:
    Other Study ID Numbers:
    • EPI-01A-001
    First Posted:
    Apr 18, 2023
    Last Update Posted:
    Apr 18, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 18, 2023